

## TADDOL-based *P,S*-bidentate diastereomeric ligands in asymmetric allylation and hydrogenation reactions

Konstantin N. Gavrilov,<sup>\*a</sup> Ilya V. Chuchelkin,<sup>a</sup> Alexey A. Shiryaev,<sup>b,c</sup> Ilya D. Firsin,<sup>a</sup> Valeria M. Trunina,<sup>a</sup> Vladislav K. Gavrilov,<sup>a</sup> Yan P. Bityak,<sup>d</sup> Denis A. Fedorov,<sup>d</sup> Vladislav S. Zimarev<sup>a,e</sup> and Nataliya S. Goulioukina<sup>\*a,e,f</sup>

<sup>a</sup> Department of Chemistry, S. A. Esenin Ryazan State University, 390000 Ryazan, Russian Federation.  
Fax: +7 4912 281 435; e-mail: k.gavrilov@365.rsu.edu.ru

<sup>b</sup> I. P. Pavlov Ryazan State Medical University, 390026 Ryazan, Russian Federation

<sup>c</sup> Scientific, Educational and Innovation Center for Chemical and Pharmaceutical Technologies, B. N. Yeltsin Ural Federal University, 620002 Ekaterinburg, Russian Federation


<sup>d</sup> Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Moscow Region, Russian Federation

<sup>e</sup> Department of Chemistry, M. V. Lomonosov Moscow State University, 119991 Moscow, Russian Federation.  
Fax: +7 495 939 1854; e-mail: goulioukina@org.chem.msu.ru

<sup>f</sup> A. N. Frumkin Institute of Physical Chemistry and Electrochemistry, Russian Academy of Sciences, 119071 Moscow, Russian Federation

DOI: 10.1016/j.mencom.2023.10.012

**Diastereomeric *P,S*-bidentate phosphoramidite ligands with TADDOL core and (1*R*,2*S*)-1,2-diphenyl-2-(phenylthio)-ethan-1-amine residue were synthesized. These ligands provided up to 76% ee in the Pd-catalyzed alkylation of (*E*)-1,3-diphenylallyl acetate with dimethyl malonate, up to 70% ee in the amination of this substrate with pyrrolidine, and 89–95% ee in the Rh-catalyzed asymmetric hydrogenation of dimethyl itaconate and methyl (*Z*)-2-acetamido-3-arylacrylates. The different contributions of diastereomeric chiral inducers to the catalytic outcome are discussed.**




**Keywords:** asymmetric catalysis, allylic substitution, palladium, hydrogenation, rhodium, phosphoramidites, *P,S*-ligands.

TADDOL-based phosphoramidites are cheap, readily available, and easily tunable so-called ‘privileged’ ligands due to their ability to promote a wide range of highly enantioselective metal-catalyzed transformations.<sup>1</sup> Here we describe the synthesis and catalytic applications of the pioneer phosphoramidite-thioethers with a TADDOL core. Mixed phosphorus/sulfur ligands attract special attention because of the electronic and steric differences between the two donor atoms: sulfur has a lower  $\sigma$ -donor and  $\pi$ -acceptor ability than phosphorus, besides divalent sulfur with two substituents creates a less hindered environment than trivalent phosphorus. These compounds have an additional important advantage over other hetero donor ligands, since a new stereogenic center is formed on sulfur upon coordination with a metal. The variation of substituents at sulfur and phosphorus atoms along with the backbone can provide very efficient structures in terms of activity and enantioselectivity in catalytic reactions.<sup>2</sup> In this article, we demonstrate the importance of the proper combination of the chiral TADDOL-derived phosphoramidite core with the additional chiral centers in the backbone chain between two donor atoms.


The condensation of (*R,R*)- or (*S,S*)-TADDOLs with  $\text{PCl}_3$  in the presence of  $\text{Et}_3\text{N}$  followed by reaction with (1*R,2S*)-1,2-diphenyl-2-(phenylthio)ethan-1-amine afforded diastereomeric *P,S*-bidentate phosphoramidites (*R,R*)-**L** and (*S,S*)-**L** (Scheme 1). The structures of these ligands were confirmed by elemental analysis and  $^1\text{H}$ ,  $^{13}\text{C}\{^1\text{H}\}$ , and  $^{31}\text{P}\{^1\text{H}\}$  NMR spectroscopy. The assignment of  $^1\text{H}$  and  $^{13}\text{C}\{^1\text{H}\}$  resonances

(excluding aromatic ones) was done using  $^1\text{H}$ – $^1\text{H}$  COSY and  $^{13}\text{C}$ – $^1\text{H}$  HSQC NMR techniques (see Online Supplementary Materials, Figures S1 and S2). Compounds (*R,R*)-**L** and (*S,S*)-**L** are stable enough to be purified by flash chromatography, they are stored and handled with ease.

The ligands were tested in Pd-catalyzed enantioselective allylic substitution reactions, which are known to be tolerant to various functional groups in substrates and proceed with a wide range of C-, N-, O-, S- and P-nucleophiles under mild conditions.<sup>3</sup> The classic reaction between (*E*)-1,3-diphenylallyl acetate **1** as the electrophile and dimethyl malonate as the C-nucleophile was performed according to the standard procedure using



Scheme 1



**Scheme 2** Reagents and conditions: i,  $\text{CH}_2(\text{CO}_2\text{Me})_2$  (1.8 equiv.),  $[\text{Pd}(\pi\text{-allyl})\text{Cl}]_2$  (1 mol%), ligand (2 or 4 mol%), BSA (1.8 equiv.), KOAc (8 mol%), solvent, room temperature, 24 h; ii, pyrrolidine (3 equiv.),  $[\text{Pd}(\pi\text{-allyl})\text{Cl}]_2$  (1 mol%), ligand (2 or 4 mol%), solvent, room temperature, 24 h.

**Table 1** Pd-catalyzed allylic alkylation of substrate **1** with dimethyl malonate.

Entry	Ligand	Molar ratio L:Pd	Solvent	Conversion (%)	ee (%) <sup>a</sup>
1	( <i>R,R</i> )- <b>L</b>	1:1	THF	100	75 ( <i>R</i> )
2	( <i>R,R</i> )- <b>L</b>	2:1	THF	89	76 ( <i>R</i> )
3	( <i>R,R</i> )- <b>L</b>	1:1	$\text{CH}_2\text{Cl}_2$	98	73 ( <i>R</i> )
4	( <i>R,R</i> )- <b>L</b>	2:1	$\text{CH}_2\text{Cl}_2$	38	71 ( <i>R</i> )
5	( <i>S,S</i> )- <b>L</b>	1:1	THF	90	56 ( <i>S</i> )
6	( <i>S,S</i> )- <b>L</b>	2:1	THF	66	55 ( <i>S</i> )
7	( <i>S,S</i> )- <b>L</b>	1:1	$\text{CH}_2\text{Cl}_2$	93	61 ( <i>S</i> )
8	( <i>S,S</i> )- <b>L</b>	2:1	$\text{CH}_2\text{Cl}_2$	32	60 ( <i>S</i> )

<sup>a</sup>The conversion of substrate **1** and enantiomeric excess of **2** were determined by HPLC (Kromasil 5-CelluCoat,  $\text{C}_6\text{H}_{14}/\text{PrOH} = 99:1$ , 0.6 ml min<sup>-1</sup>, 254 nm, *t*(*R*) = 21.4 min, *t*(*S*) = 23.2 min). The absolute configurations of **2** were assigned by comparison with the literature<sup>4</sup> HPLC retention times.

$[\text{Pd}(\pi\text{-allyl})\text{Cl}]_2$  as the palladium source and a combined base of *N,O*-bis(trimethylsilyl)acetamide (BSA) with a catalytic amount of KOAc (Scheme 2). Ligand (*R,R*)-**L** provided the formation of product (*R*)-**2** with 71–76% ee and good to quantitative conversion of the starting substrate **1** in most cases (Table 1, entries 1–4). As a solvent, THF was slightly preferable to dichloromethane. Ligand (*S,S*)-**L** exhibited lower catalytic activity and selectivity and afforded product (*S*)-**2** with enantiomeric excess of only up to 61% (entries 5–8). The chirality of phosphoramidite moiety seems to be the major factor in controlling the enantioselectivity. For both diastereomeric ligands the asymmetric induction was insensitive to the L/Pd molar ratio.


As for the Pd-catalyzed allylic amination of **1** using pyrrolidine as the N-nucleophile (see Scheme 2, Table 2), all experiments were carried out in  $\text{CH}_2\text{Cl}_2$  (no conversion of **1** was observed when the reaction was carried out in THF). Phosphoramidites (*R,R*)-**L** and (*S,S*)-**L** gave almost equal enantioselectivity (up to 67 and 70% ee, respectively), but the catalytic activity was higher in the former case. Similarly to the allylic alkylation, the application of diastereomers of **L** led to the formation of enantiomeric products **3**, and the L/Pd molar ratio had no noticeable effect on the asymmetric induction.

To expand the range of possible applications of the novel ligands, we examined the Rh-catalyzed enantioselective

**Table 2** Pd-catalyzed allylic amination of substrate **1** with pyrrolidine.

Entry	Ligand	Molar ratio L:Pd	Solvent	Conversion (%)	ee (%) <sup>a</sup>
1	( <i>R,R</i> )- <b>L</b>	1:1	$\text{CH}_2\text{Cl}_2$	45	67 ( <i>S</i> )
2	( <i>R,R</i> )- <b>L</b>	2:1	$\text{CH}_2\text{Cl}_2$	100	66 ( <i>S</i> )
3	( <i>S,S</i> )- <b>L</b>	1:1	$\text{CH}_2\text{Cl}_2$	7	65 ( <i>R</i> )
4	( <i>S,S</i> )- <b>L</b>	2:1	$\text{CH}_2\text{Cl}_2$	12	70 ( <i>R</i> )

<sup>a</sup>The conversion of substrate **1** and enantiomeric excess of **3** were determined by HPLC (Daicel Chiralcel OD-H,  $\text{C}_6\text{H}_{14}/\text{PrOH} = 95:5$ , 0.4 ml min<sup>-1</sup>, 254 nm, *t*(*R*) = 9.7 min, *t*(*S*) = 10.2 min). The absolute configurations of **3** were assigned by comparison with the literature<sup>5</sup> HPLC retention times.



**Scheme 3** Reagents and conditions: i,  $\text{H}_2$  (6 atm),  $[\text{Rh}(\text{Cod})_2]\text{BF}_4$  (1 mol%), ligand (1 mol%),  $\text{CH}_2\text{Cl}_2$ , room temperature, 24 h.

**Table 3** Rh-catalyzed asymmetric hydrogenation of substrates **4a–d**.

Entry	Ligand	Substrate	Conversion (%)	ee (%) <sup>a</sup>
1	( <i>R,R</i> )- <b>L</b>	<b>4a</b>	100	91 ( <i>S</i> )
2	( <i>R,R</i> )- <b>L</b>	<b>4b</b>	100	89 ( <i>R</i> )
3	( <i>R,R</i> )- <b>L</b>	<b>4c</b>	100	94 ( <i>R</i> )
4	( <i>R,R</i> )- <b>L</b>	<b>4d</b>	100	95 ( <i>R</i> )
5	( <i>S,S</i> )- <b>L</b>	<b>4a</b>	0	–
6	( <i>S,S</i> )- <b>L</b>	<b>4b</b>	100	7 ( <i>R</i> )
7	( <i>S,S</i> )- <b>L</b>	<b>4c</b>	95	1 ( <i>S</i> )
8	( <i>S,S</i> )- <b>L</b>	<b>4d</b>	98	8 ( <i>S</i> )

<sup>a</sup>The conversion of substrates **4a–d** and enantiomeric excesses of **5a–d** were determined by HPLC (**5a**, Daicel Chiralcel OD-H,  $\text{C}_6\text{H}_{14}/\text{PrOH} = 98:2$ , 0.8 ml min<sup>-1</sup>, 215 nm, *t*(*R*) = 9.2 min, *t*(*S*) = 16.1 min; **5b**, Daicel Chiralcel OD-H,  $\text{C}_6\text{H}_{14}/\text{PrOH} = 4:1$ , 0.6 ml min<sup>-1</sup>, 215 nm, *t*(*R*) = 10.0 min, *t*(*S*) = 12.4 min; **5c**, Daicel Chiralcel OD-H,  $\text{C}_6\text{H}_{14}/\text{PrOH} = 9:1$ , 1.0 ml min<sup>-1</sup>, 219 nm, *t*(*R*) = 10.4 min, *t*(*S*) = 14.2 min and **5d**, Daicel Chiralcel OD-H,  $\text{C}_6\text{H}_{14}/\text{PrOH} = 9:1$ , 0.8 ml min<sup>-1</sup>, 215 nm, *t*(*R*) = 9.0 min, *t*(*S*) = 11.8 min). The absolute configurations of **5a–d** were assigned by comparison with the HPLC retention times reported [refs. 4(a), 6].

hydrogenation of prochiral unsaturated esters **4a–d** (Scheme 3). Like the allylic substitution reactions mentioned above, Rh-catalyzed hydrogenation is widely used to produce a large number of enantio-enriched (enantiopure) synthetic precursors of valuable natural and unnatural compounds.<sup>3</sup> The cationic rhodium catalysts were prepared *in situ* by treating  $[\text{Rh}(\text{Cod})_2]\text{BF}_4$  with 1 equiv. of the corresponding ligand in  $\text{CH}_2\text{Cl}_2$ . The dramatic difference between the diastereomers of **L** was observed. The usage of (*R,R*)-**L** resulted in the quantitative conversion of dimethyl itaconate **4a** or methyl (*Z*)-2-acetamido-3-arylacrylates **4b–d** and good asymmetric induction: products (*S*)-**5a** and (*R*)-**5b–d** were formed with 89–95% ee (Table 3, entries 1–5). The diastereomeric ligand (*S,S*)-**L** demonstrated a pronounced mismatch effect and either showed a poor enantiocontrol (no more than 8% ee, entries 6–8), or turned out to be completely inactive (entry 5).

In summary, the obtained *P,S*-bidentate phosphoramidites with TADDOL framework (*R,R*)-**L** and (*S,S*)-**L** are promising chirality inducers exhibiting notable results in asymmetric Pd-catalyzed allylic substitution and Rh-catalyzed hydrogenation. Additional studies highlighting the potential of these and similar ligands in other enantioselective reactions are now in progress in our laboratories.

This work was supported by the Russian Science Foundation (grant no. 19-13-00197) and was performed using NMR equipment of MIPT Shared Facilities Center.

#### Online Supplementary Materials

Supplementary data associated with this article can be found in the online version at doi: 10.1016/j.mencom.2023.10.012.

#### References

- (a) H. Pellissier, *Tetrahedron*, 2008, **64**, 10279; (b) H. W. Lam, *Synthesis*, 2011, 2011; (c) J. Pedroni and N. Cramer, *Chem. Commun.*, 2015, **51**, 17647; (d) H. Pellissier, *Coord. Chem. Rev.*, 2023, **482**, 215079.
- (a) H. Pellissier, *Tetrahedron*, 2007, **63**, 1297; (b) M. Mellah, A. Voituriez and E. Schulz, *Chem. Rev.*, 2007, **107**, 5133; (c) J. Margalef, O. Pàmies,

M. A. Pericàs and M. Diéguez, *Chem. Commun.*, 2020, **56**, 10795;  
 (d) B. Shi, W.-J. Xiao and L.-Q. Lu, *Synlett*, 2023, doi: 10.1055/a-2072-3025.

3 (a) Z. Lu and S. Ma, *Angew. Chem., Int. Ed.*, 2008, **47**, 258;  
 (b) S. Noreen, A. F. Zahoor, S. Ahmad, I. Shahzadi, A. Irfan and S. Faiz, *Curr. Org. Chem.*, 2019, **23**, 1168; (c) O. Pàmies, J. Margalef, S. Cañellas, J. James, E. Judge, P. J. Guiry, C. Moberg, J.-E. Bäckvall, A. Pfaltz, M. A. Pericàs and M. Diéguez, *Chem. Rev.*, 2021, **121**, 4373;  
 (d) P. Etayo and A. Vidal-Ferran, *Chem. Soc. Rev.*, 2013, **42**, 728;  
 (e) A. Cabré, X. Verdaguer and A. Riera, *Chem. Rev.*, 2022, **122**, 269.

4 (a) E. B. Benetskiy and C. Bolm, *Tetrahedron: Asymmetry*, 2011, **22**, 373; (b) K. E. Thiesen, K. Maitra, M. M. Olmstead and S. Attar, *Organometallics*, 2010, **29**, 6334; (c) M. Ramillien, N. Vanthuyne, M. Jean, D. Gherase, M. Giorgi, J.-V. Naubron, P. Piras and C. Roussel, *J. Chromatogr. A*, 2012, **1269**, 82.

5 (a) J. Chen, F. Lang, D. Li, L. Cun, J. Zhu, J. Deng and J. Liao, *Tetrahedron: Asymmetry*, 2009, **20**, 1953; (b) M. Majdecki, J. Jurczak and T. Bauer, *ChemCatChem*, 2015, **7**, 799.

6 (a) K. N. Gavrilov, S. V. Zheglov, E. A. Rastorguev, N. N. Groshkin, M. G. Maksimova, E. B. Benetsky, V. A. Davankov and M. T. Reetz, *Adv. Synth. Catal.*, 2010, **352**, 2599; (b) D. Carmichael, G. Goldet, J. Klankermayer, L. Ricard, N. Seeboth and M. Stankevič, *Chem. – Eur. J.*, 2007, **13**, 5492; (c) L. Navarre, R. Martinez, J.-P. Genet and S. Darses, *J. Am. Chem. Soc.*, 2008, **130**, 6159.

Received: 30th June 2023; Com. 23/7208